Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

74 questions · 76 findings · 31 reviews

No studies found 14 · 18.4%GRADE not reported 9 · 11.8%Very low 16 · 21.1%Low 18 · 23.7%Moderate 13 · 17.1%High 6 · 7.9%

Standard‐dose VKA plus single antiplatelet agent vs one antiplatelet agent

Major bleeding (minor cerebral hemorrhage) · people with antiphospholipid syndrome, with previous stroke

It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes major bleeding (minor cerebral hemorrhage) compared with single antiplatelet agent (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).

1 finding from 1 review

DOAC vs placebo

Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).

1 finding from 1 review

Vitamin K antagonists vs heparin

Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Vitamin K antagonists showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with heparin (low certainty).

1 finding from 1 review

DOAC vs heparin

Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with heparin (high certainty).

1 finding from 1 review

Heparin vs placebo

Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Heparin leads to higher bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (high certainty).

1 finding from 1 review

Anticoagulant with or without ASA vs ASA only

Minor bleeding · people with antiphospholipid antibodies and no history of thrombosis

Anticoagulant with or without ASA may leads to higher bleeding ‐ minor (not requiring hospital admission) Median compared with ASA only (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion prior to surgery vs alternative treatment

Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with a low platelet count

It is very uncertain whether prophylactic platelet transfusion prior to surgery changes number of participants with minor procedure‐related bleeding within… compared with alternative treatments (very low certainty).

1 finding from 1 review

Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery

Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with a low platelet count

It is very uncertain whether prophylactic platelet transfusion prior to surgery changes the number of participants with minor procedure‐related bleeding… compared with no prophylactic platelet transfusion prior to surgery (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs no prophylaxis

All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).

1 finding from 1 review